| BIOCRYST PHARMACEUTICALS |
| USA |
| Gesundheit |
| US09058V1035 / 896047 |
| BO1 (Frankfurt) / BCRX (NASDAQ) |
| FRA:BO1, ETR:BO1, BO1:GR, NASDAQ:BCRX |
| - |
| https://www.biocryst.com/ |
|
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for rare diseases, with a primary emphasis on hereditary angioedema (HAE). Its commercial portfolio is centered on ORLADEYO, an oral therapy..
>Volltext.. |
| 1693.79 Mio. EUR |
| 2093.27 Mio. EUR |
| 876.67 Mio. EUR |
| 374.33 Mio. EUR |
| -327.92 Mio. EUR |
| -1.24 EUR |
| 755.13 Mio. EUR |
| 88.89 Mio. EUR |
| 319.64 Mio. EUR |
| 1.92 |
| 66.05% |
| -4143.6% |
| - |
| - |
| - |
| - |
| BIOCRYST |
| 21.11.26 |
|